Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 26;147(12):10618-10628.
doi: 10.1021/jacs.5c00769. Epub 2025 Mar 11.

The Ulcerative Colitis-Associated Gene NXPE1 Catalyzes Glycan Modifications on Colonic Mucin

Affiliations

The Ulcerative Colitis-Associated Gene NXPE1 Catalyzes Glycan Modifications on Colonic Mucin

Ranad Humeidi et al. J Am Chem Soc. .

Abstract

Colonic mucus forms a first line of defense against bacterial invasion while providing nutrition to support coinhabiting microbes in the gut. Mucus is composed of polymeric networks of mucin proteins, which are heavily modified post-translationally. The full compendium of enzymes responsible for these modifications and their roles in health and disease remain incompletely understood. Herein, we determine the biochemical function of NXPE1, a gene implicated in ulcerative colitis (UC), and demonstrate that it encodes an acetyltransferase that modifies mucin glycans. Specifically, NXPE1 utilizes acetyl-CoA to regioselectively modify the mucus sialic acid, 5-N-acetylneuraminic acid (Neu5Ac), at the 9-OH group to generate 9-O-acetylated Neu5Ac (Neu5,9Ac2). We further demonstrate that colonic organoids derived from donors harboring the missense variant NXPE1 G353R, which is protective against UC, exhibit severely impaired acetylation of Neu5Ac on mucins. Together, our findings support a model in which NXPE1 masks the alcohols of mucus sialoglycans via acetylation, which is important for modulating mucus barrier properties that limit interactions with commensal microbes.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

R.J.X. is co-founder of Jnana Therapeutics, Scientific Advisory Board member at Nestlé and Magnet BioMedicine, and Board Director at MoonLake Immunotherapeutics; these organizations had no roles in this study. All other authors declare no conflicts of interest.

References

    1. Weisman MH, et al., Inflammatory Bowel Disease prevalence: Surveillance data from the U.s. national Health and Nutrition Examination Survey. Prev. Med. Rep 33, 102173 (2023). - PMC - PubMed
    1. Graham DB, Xavier RJ, Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature 578, 527–539 (2020). - PMC - PubMed
    1. Plichta DR, Graham DB, Subramanian S, Xavier RJ, Therapeutic opportunities in inflammatory bowel disease: Mechanistic dissection of host-microbiome relationships. Cell 178, 1041–1056 (2019). - PMC - PubMed
    1. Uhlig HH, Powrie F, Translating immunology into therapeutic concepts for inflammatory bowel disease. Annu. Rev. Immunol 36, 755–781 (2018). - PubMed
    1. Jostins L, et al., Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012). - PMC - PubMed

LinkOut - more resources